Gil José Pedro, Fançony Cláudia
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Faculty of Sciences, BioISI-Biosystems and Integrative Sciences Institute, University of Lisbon, Lisbon, Portugal.
Front Pharmacol. 2021 Nov 1;12:759422. doi: 10.3389/fphar.2021.759422. eCollection 2021.
The capacity of the lethal parasite to develop resistance against anti-malarial drugs represents a central challenge in the global control and elimination of malaria. Historically, the action of drug transporters is known to play a pivotal role in the capacity of the parasite to evade drug action. MRPs (Multidrug Resistance Protein) are known in many phylogenetically diverse groups to be related to drug resistance by being able to handle a large range of substrates, including important endogenous substances as glutathione and its conjugates. MRPs are associated with in vivo and in vitro altered drug response, and might be important factors for the development of multi-drug resistance phenotypes, a latent possibility in the present, and future, combination therapy environment. Information on MRPs is scattered in the literature, with no specialized review available. We herein address this issue by reviewing the present state of knowledge.
致命疟原虫产生抗疟疾药物耐药性的能力是全球疟疾控制和消除工作面临的核心挑战。从历史上看，药物转运蛋白的作用在疟原虫逃避药物作用的能力中起着关键作用。在许多系统发育多样的群体中，多药耐药蛋白（MRP）因能够处理多种底物（包括重要的内源性物质如谷胱甘肽及其共轭物）而与耐药性相关。MRP与体内和体外药物反应改变有关，可能是多药耐药表型发展的重要因素，在当前和未来的联合治疗环境中都存在这种潜在可能性。关于MRP的信息分散在文献中，尚无专门的综述。我们在此通过回顾现有知识状态来解决这个问题。
